Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Revelation Biosciences, Inc. - Common Stock (NQ:REVB)

0.8250 -0.0150 (-1.79%)
Streaming Delayed Price Updated: 10:06 AM EST, Jan 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 73,577
Open 0.8100
Bid (Size) 0.8201 (100)
Ask (Size) 0.8300 (100)
Prev. Close 0.8400
Today's Range 0.8036 - 0.8300
52wk Range 0.7066 - 20.16
Shares Outstanding 6,297,303
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI
Via ACCESS Newswire
News headline image
Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026)
Via ACCESS Newswire

Performance

YTD
+1.5%
+1.5%
1 Month
-3.8%
-3.8%
3 Month
-30.1%
-30.1%
6 Month
-73.3%
-73.3%
1 Year
-95.8%
-95.8%

More News

Read More
News headline image
Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Via ACCESS Newswire
News headline image
Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development
Via ACCESS Newswire
News headline image
Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting
Via ACCESS Newswire
Revelation Biosciences Stock Slides 17% After Company Reports 3 Severe Adverse Events In Early Stage Trial Of Inflammation Drug ↗
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Via Benzinga
News headline image
Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Via Benzinga
News headline image
REVELATION BIOSCIENCES INC (NASDAQ:REVB) Reports Q3 2025 Loss, Announces Groundbreaking Clinical Data and Improved Cash Runway ↗
Via Chartmill
News headline image
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025
Via ACCESS Newswire
News headline image
Revelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record Date
Via ACCESS Newswire
News headline image
Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Via Benzinga
News headline image
Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Via Benzinga
News headline image
Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
Via Benzinga
News headline image
Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Via Benzinga
News headline image
Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study
Via ACCESS Newswire
News headline image
Revelation Biosciences Inc (NASDAQ:REVB) Reports Wider-Than-Expected Q2 2025 Loss, Extends Cash Runway to Year-End ↗
Via Chartmill
News headline image
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025
From Revelation Biosciences, Inc.
Via Business Wire
News headline image
Revelation Biosciences, Inc. Congratulates Its Former Chairman of the Board, George Tidmarsh, on His Appointment as the Head of the FDA Center for Drug Evaluation and Research
From Revelation Biosciences, Inc.
Via Business Wire
News headline image
Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study
From Revelation Biosciences, Inc.
Via Business Wire

Frequently Asked Questions

Is Revelation Biosciences, Inc. - Common Stock publicly traded?
Yes, Revelation Biosciences, Inc. - Common Stock is publicly traded.
What exchange does Revelation Biosciences, Inc. - Common Stock trade on?
Revelation Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Revelation Biosciences, Inc. - Common Stock?
The ticker symbol for Revelation Biosciences, Inc. - Common Stock is REVB on the Nasdaq Stock Market
What is the current price of Revelation Biosciences, Inc. - Common Stock?
The current price of Revelation Biosciences, Inc. - Common Stock is 0.8250
When was Revelation Biosciences, Inc. - Common Stock last traded?
The last trade of Revelation Biosciences, Inc. - Common Stock was at 01/22/26 10:06 AM ET
What is the market capitalization of Revelation Biosciences, Inc. - Common Stock?
The market capitalization of Revelation Biosciences, Inc. - Common Stock is 5.20M
How many shares of Revelation Biosciences, Inc. - Common Stock are outstanding?
Revelation Biosciences, Inc. - Common Stock has 5M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.